4-hydroxytamoxifen

4-Hydroxytamoxifen (ICI 79280) 是 Tamoxifen 的活性代谢产物，是一种雌激素受体调节剂 (SERM)，具有选择性和口服有效性。4-Hydroxytamoxifen 具有抗肿瘤活性，可用于乳腺癌的研究。

(E Z)-4-Hydroxytamoxifen (Afimoxifene) 是一种新的雌激素抑制剂，多用于多种雌激素依赖性疾病的研究，包括周期性乳房疼痛和男性乳房发育症。

(E)-4-Hydroxytamoxifen is a less active isomer of (Z)-4-hydroxytamoxifen and also is an estrogen receptor modulator.

It is a metabolite of tamoxifen and an estrogen receptor modulator.

4'-Hydroxytamoxifen TFA, 作为Tamoxifen的一个代谢物盐形态，对ER具有比Tamoxifen更高的亲和性。此化合物在人类子宫内膜腺癌细胞中能够诱导非凋亡细胞毒性。

SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor. SIM010603 inhibited stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC(50) values between 5.0 and 68.1 nmol l. SIM010603 inhibited the phosphorylation of PDGFR-β and VEGFR-2. Moreover, SIM010603 inhibited endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis.

Endoxifen ((E Z)-Endoxifen) 是 Tamoxifen 的关键活性代谢物，能抑制芳香酶的活性，与雌激素受体有较高的亲和力和特异性。它有潜力研究乳腺癌。

SNIPER(ER)-87 is a chemical compound composed of a derivative of the inhibitor of apoptosis protein (IAP) ligand LCL161 conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen using a PEG linker. It effectively degrades the ERα protein with an IC50 value of 0.097 μM. Within cells, SNIPER(ER)-87 selectively recruits XIAP to ERα, and XIAP functions as the primary E3 ubiquitin ligase responsible for the degradation of ERα induced by SNIPER(ER)-87[1][2].

Endoxifen, also known as N-desmethyl-4-hydroxytamoxifen, is a chemical that is under development for estrogen receptor-positive breast cancer. It is also being evaluated as an antipsychotic for treatment of mania and other psychotic disorders. Endoxifen is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group. It is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce afimoxifene (4-hydroxytamoxifen) and endoxifen.

Isoerysenegalensein E shows anti-estrogenic activity comparable to that of 4-hydroxytamoxifen, a typical estrogen receptor antagonist. It shows significant cytotoxicity against HL-60 cells, it induces apoptosis in HL-60 cells through activation of the cas